Abstract
Prospective observational studies have shown that arterial stiffness is a strong and independent predictor of cardiovascular disease in hemodialysis patients. Recent evidence further supports that arterial hardening predicts cardiovascular and all-cause mortality in peritoneal dialysis patients, renal transplant recipients and patients with chronic kidney disease (CKD) not on dialysis. Of note, dissociation of arterial stiffness with blood pressure reduction were related to worsened cardiovascular outcome in kidney disease patients, suggesting that arterial stiffness may not only be a predictor, but also a true risk factor, representing a specific and potentially reversible pattern of outward arterial remodeling in these individuals. On this basis, arterial stiffness has emerged as a novel therapeutic target for cardiovascular risk reduction in patients with CKD; specific interventions, such as renin-angiotensin-system blockade, use of statins, and decrease of calcium- phosphate product may delay the progression of arteriosclerotic process. This article summarizes the accumulated evidence from clinical and epidemiological studies regarding the prognostic significance of arterial stiffening on cardiovascular outcomes and provides insights on possible treatment strategies for arterial stiffness attenuation in patients with CKD.
Keywords: Arterial stiffness, arterial remodeling, chronic kidney disease, end-stage renal disease, cardiovascular morbidity, cardiovascular mortality.
Current Vascular Pharmacology
Title:Arterial Stiffness: A Novel Cardiovascular Risk Factor in Kidney Disease Patients
Volume: 13 Issue: 2
Author(s): Panagiotis I. Georgianos, Pantelis A. Sarafidis and Anastasios N. Lasaridis
Affiliation:
Keywords: Arterial stiffness, arterial remodeling, chronic kidney disease, end-stage renal disease, cardiovascular morbidity, cardiovascular mortality.
Abstract: Prospective observational studies have shown that arterial stiffness is a strong and independent predictor of cardiovascular disease in hemodialysis patients. Recent evidence further supports that arterial hardening predicts cardiovascular and all-cause mortality in peritoneal dialysis patients, renal transplant recipients and patients with chronic kidney disease (CKD) not on dialysis. Of note, dissociation of arterial stiffness with blood pressure reduction were related to worsened cardiovascular outcome in kidney disease patients, suggesting that arterial stiffness may not only be a predictor, but also a true risk factor, representing a specific and potentially reversible pattern of outward arterial remodeling in these individuals. On this basis, arterial stiffness has emerged as a novel therapeutic target for cardiovascular risk reduction in patients with CKD; specific interventions, such as renin-angiotensin-system blockade, use of statins, and decrease of calcium- phosphate product may delay the progression of arteriosclerotic process. This article summarizes the accumulated evidence from clinical and epidemiological studies regarding the prognostic significance of arterial stiffening on cardiovascular outcomes and provides insights on possible treatment strategies for arterial stiffness attenuation in patients with CKD.
Export Options
About this article
Cite this article as:
Georgianos I. Panagiotis, Sarafidis A. Pantelis and Lasaridis N. Anastasios, Arterial Stiffness: A Novel Cardiovascular Risk Factor in Kidney Disease Patients, Current Vascular Pharmacology 2015; 13 (2) . https://dx.doi.org/10.2174/15701611113119990147
DOI https://dx.doi.org/10.2174/15701611113119990147 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Small Animal Cardiac Magnetic Resonance Imaging
Current Cardiology Reviews Effects of Tai Chi Exercise on Physical and Psychological Health of Older People
Current Aging Science Development of Improved Factor VIII Molecules and New Gene Transfer Approaches for Hemophilia A
Current Gene Therapy Metabolic Effects of a Diet with Inulin-Enriched Pasta in Healthy Young Volunteers
Current Pharmaceutical Design Role of AGEs-RAGE System in Cardiovascular Disease
Current Pharmaceutical Design Lifestyle Changes and Pharmacological Risk Factor Modification for Effective Vascular Disease Prevention
Vascular Disease Prevention (Discontinued) Recombinant Protein Based Therapeutics for IPF
Inflammation & Allergy - Drug Targets (Discontinued) MicroRNAs: Important Epigenetic Regulators in Osteoarthritis
Current Genomics Baseline Levels of Interleukine-6, Tumor-Necrosis Factor-Alpha and C-Reactive Protein in Treatment Naive Human Immunodeficiency Virus Infected Patients-A Study from a Tertiary-Care Hospital in Eastern India
Current Biomarkers (Discontinued) Oxidative Modification of Lipoproteins: Mechanisms, Role in Inflammation and Potential Clinical Applications in Cardiovascular Disease
Current Pharmaceutical Design microRNAs in Cancer: Lessons from Melanoma
Current Pharmaceutical Design Alzheimer’s Disease and Environmental Exposure to Lead: The Epidemiologic Evidence and Potential Role of Epigenetics
Current Alzheimer Research Improving RBC K Transport and Hemoglobin-O2 Binding by Amiloride: A Novel Therapeutic Approach for Reversion of Angina and Myocardial Ischemia in Coronary Heart Diseases
Recent Patents on Cardiovascular Drug Discovery The Janus Face of Adenosine: Antiarrhythmic and Proarrhythmic Actions
Current Pharmaceutical Design The Relationship Between Hypertensive Retinopathy and Angiotensin Converting Enzyme Gene Polymorphism
Cardiovascular & Hematological Disorders-Drug Targets Editorial (Hot Topic: The New Kids on the Block: Oral Direct IIa and Xa Inhibitors Enter the Proscenium of Anticoagulation Treatment)
Current Clinical Pharmacology Oxidative Stress in Cardiovascular Disease: A New Avenue Toward Future Therapeutic Approaches
Recent Patents on Cardiovascular Drug Discovery Non-Analgesic Effects of Opioids: Opioids and the Endocrine System
Current Pharmaceutical Design Literature Review: Use of Family History for Primary Paediatric Care as the Next Step Towards use of Genomics in Healthcare
Current Pediatric Reviews Endothelial Dysfunction: Methods of Assessment & Implications for Cardiovascular Diseases
Current Pharmaceutical Design